# Optimizing HPV Vaccine Introduction in Shanghai, China

> **NCT03972813** · NA · TERMINATED · sponsor: **University of Michigan** · enrollment: 1021 (actual)

## Conditions studied

- Vaccine Refusal

## Interventions

- **BEHAVIORAL:** Broadened information about cancers
- **BEHAVIORAL:** Information about STDs
- **BEHAVIORAL:** Information about infectious disease
- **BEHAVIORAL:** Recommendation for children 12 years old
- **BEHAVIORAL:** Recommendation for children 18 years old
- **BEHAVIORAL:** Standard age information
- **BEHAVIORAL:** Cervical cancer
- **BEHAVIORAL:** Blank information about communicability

## Key facts

- **NCT ID:** NCT03972813
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-28
- **Primary completion:** 2019-08-31
- **Final completion:** 2019-08-31
- **Target enrollment:** 1021 (ACTUAL)
- **Why stopped:** Due to COVID-19, we were unable to continue data collection in China.
- **Last updated:** 2025-01-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03972813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03972813, "Optimizing HPV Vaccine Introduction in Shanghai, China". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03972813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*